Evaluating the Treatment Outcomes of Tafasitamab in Patients With Relapsed/ Refractory Diffuse Large B-cell Lymphoma: a Real-world Evidence Study
NCT07709624 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 50
Last updated 2026-07-16
Summary
To evaluate the efficacy of tafasitamab in patients with relapsed/ refractory diffuse large B-cell lymphoma
\*To evaluate best objective response rate (ORR)
Conditions
Interventions
- DRUG
-
Minjuvi
Observation study, collect data only
Sponsors & Collaborators
-
TTY Biopharm
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-12-01
- Primary Completion
- 2030-01-28
- Completion
- 2030-12-31
Countries
- Taiwan
Study Locations
More Related Trials
-
Efficacy and Safety of Sequential Autologous Hematopoietic Stem Cell Transplantation Combined With Tafasitamab, Lenalidomide, and Standard Immunochemotherapy for Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT07621406 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL
NCT04134936 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma
NCT07030699 ·Status: WITHDRAWN ·Phase: PHASE2
-
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
NCT04824092 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Clinical Study of U29 Injection (CD30-CART) in Patients With CD30-Positive Relapsed/Refractory Lymphoma
NCT07453446 ·Status: WITHDRAWN ·Phase: PHASE1
-
CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL
NCT05659628 ·Status: RECRUITING ·Phase: PHASE1
-
CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma
NCT07461831 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT06521255 ·Status: RECRUITING ·Phase: PHASE3
-
Observational Retrospective Cohort Study of Systemic Therapies for R/R DLBCL
NCT04697160 ·Status: COMPLETED
-
Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)
NCT03298412 ·Status: TERMINATED ·Phase: PHASE2
-
Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients
NCT07473167 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
NCT03009344 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL
NCT05658562 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients
NCT03630159 ·Status: COMPLETED ·Phase: PHASE1
-
Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
NCT05626322 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Comparison of Clinical Outcomes Among Patients Treated With Tisagenlecleucel
NCT05541328 ·Status: COMPLETED
-
TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
NCT03123393 ·Status: TERMINATED ·Phase: PHASE2
-
Observational Study of Diffuse Large B Cell Primary Breast Lymphomas Treated With RCHOP +/- XRT
NCT01144754 ·Status: TERMINATED
-
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
NCT07189065 ·Status: RECRUITING ·Phase: PHASE2
-
A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL
NCT06779435 ·Status: RECRUITING
-
Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NCT02391116 ·Status: COMPLETED ·Phase: PHASE2
-
IT-TT as an Effective and Well-Tolerated Strategy for CNS Prop in High-Risk DLBCL: a Prospective Ph II Study
NCT07493486 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients
NCT03876028 ·Status: TERMINATED ·Phase: PHASE1
-
Investigator Initiated Study to Assess the Safety of Combination of CLS-015 With Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive Large B Cell Lymphoma at Lymphodepletion.
NCT07361224 ·Status: RECRUITING ·Phase: PHASE1
-
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
NCT05890352 ·Status: RECRUITING ·Phase: PHASE2